8-K - Seres Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Seres Therapeutics, Inc. announced its financial results for the quarter on March 12, 2026, under Item 2.02. The Company also posted an updated corporate presentation on its website under Item 7.01, with Exhibits 99.1 and 99.2 furnished in connection therewith.

Key Takeaways

1Announcement date: March 12, 2026

2Item 2.02: Results of Operations and Financial Condition

3Item 7.01: Regulation FD Disclosure via updated corporate presentation

4Exhibits 99.1 (Item 2.02) and 99.2 (Item 7.01) furnished

5Presentation posted in 'Investors and News' section of www.serestherapeutics.com

Current Report Details

Event Type

Financial Results

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

. Results of Operations and Financial Condition. On March 12, 2026, Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and

Financial Results

7.01

. Regulation FD Disclosure. On March 12, 2026, the Company posted an updated corporate presentation in the “Investors and News” portion of its website at www.se

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits The following Exhibits 99.1 and 99.2 relate to Items 2.02 and 7.01, respectively, and shall be deemed to be fu

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2